Harpoon Therapeutics Inc

Harpoon Therapeutics — Investor Presentation (January 2022)

40 slides from Harpoon Therapeutics's investor presentation, Jan 11, 2022

  1. Slide 1: Spearheading Immunotherapies Investor Presentation January 2022

    Spearheading Immunotherapies Investor Presentation January 2022 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate” and similar expressions (as well as other words or expre

  3. Slide 3: Clinical-Stage Immuno-Oncology Company Advancing a Novel Portfolio of T Cell Engagers

    Clinical-Stage Immuno-Oncology Company Advancing a Novel Portfolio of T Cell Engagers Redirecting T Cells to Become Cancer Killers Strong Capabilities Broad Pipeline in Immuno-Oncology Novel T Cell Engaging Platforms Deep expertise in oncology, T cell engagement, and protein engineering Well-positio

  4. Slide 4: Broad Pipeline of Immuno-Oncology Programs

    TriTAC Oncology ProTriTAC Oncology TriTAC-XR Oncology/ Non-Oncology Program Stage of Development Preclinical Phase 1 Phase 2 HPN328 (DLL3) Small Cell Lung Cancer & Other Tumors HPN2171 (BCMA) Multiple Myeloma HPN536 (MSLN) Ovarian, Pancreatic & Other Solid Tumors HPN424 (PSMA) Prostate Cancer HPN601

  5. Slide 5: HPN328 TriTAC Targeting DLL3

    HPN328 TriTAC Targeting DLL3

  6. Slide 6: Small Cell Lung Cancer Comprises ~13% of All Lung Cancers

    Small Cell Lung Cancer (SCLC) Comprises ~13% of All Lung Cancers; Aggressive Disease and Outsized Unmet Need Chemo- and/or radiation therapy has been the SoC as frontline treatment; Limited utilization due to suboptimal efficacy and significant toxicity Most patients relapse Recently-approved immuno

  7. Slide 7: HPN328 Phase 1/2 Study

    HPN328 Phase 1/2 Study An Open-Label, Multi-Center, Dose Escalation / Expansion, Safety & PK Study Target population Small cell lung cancer relapsed after platinum chemotherapy Other malignancies with high grade neuroendocrine features R/R to standard of care (SOC) or no SOC available Trial objectiv

  8. Slide 8: HPN328: Dose Cohorts

    HPN328: Dose Cohorts 480-Fold Escalation Accomplished Data as of December 2, 2021 Dose Level (µg/week) n 15 1 45 1 135 1 405 3 1215 4 3600 1 3600 (priming)→7200 (target) 4 Total 15

  9. Slide 9: HPN328 Baseline Demographics

    HPN328 Baseline Demographics 93% of Patients Had Prior Anti-PD-1/PD-L1 Treatment *Other NET: Colorectal, Retroperitoneal, Pancreatic, Thymic Data as of December 2, 2021 Baseline Characteristics Total N = 15 Age (yr), Median (range) 61 (43 – 73) ECOG performance status 0-1, n (%) 15 (100) Brain / Liv

  10. Slide 10: HPN328: Safety and Tolerability

    No dose-limiting toxicities observed Maximum tolerated dose not reached CRS events: 5 of 15 patients experienced CRS (G1-2) All CRS events were managed with standard medications and resolved within hours When CRS occurred, it typically followed the first dose and did not recur on subsequent dosing T

  11. Slide 11: HPN328 Time on Treatment

    HPN328 Time on Treatment 3600 3600 3600 uPR -38% TL chg (week 9) Confirmed PR -53% TL chg (week 9) -21% TL chg (Week 9) -27% TL chg (Week 9) Dose Increase SCLC Prior PD1/L1 inhibitor Ongoing NEPC NET Other * % Target Lesion Reduction from Baseline -X% Objective Response (RECIST v1.1) CR, PR Dose (μg

  12. Slide 12: HPN328 SCLC Patients Anti-tumor Activity at Higher Doses

    HPN328 SCLC patients Anti-tumor Activity at Higher Doses, Including Confirmed PR At doses of ≥1215μg/wk: 3/4 SCLC patients had target lesion (TL) reductions Dose (μg/week) * * * * * On study treatment aRECIST 1.1 Criteria: -Partial Response: 30% or greater TL reduction -Progressive Disease: 20% incr

  13. Slide 13: HPN328 Patient Case One: SCLC

    61-year-old female Diagnosed in January 2021 with extensive SCLC Location of metastases: TLs: lung, liver x2, lymph nodes x2 Non-TLs: lung x2, liver Prior systemic treatment: carboplatin etoposide+atezolizumab Time on most recent prior systemic treatment: 20.1 weeks Upon study entry, stable disease

  14. Slide 14: HPN328 Patient Case One: SCLC Imaging

    Pre-Treatment Week 6 Post-Treatment Week 10 Post-Treatment 38% reduction at wk 6 53% reduction at wk 10 HPN328 Patient Case One: SCLC 53% Reduction in Sum of Target Lesion Diameters at Week 10 Confirmed PR Lymph Node Lung Liver Data as of December 2, 2021

  15. Slide 15: HPN328 Patient Case Two: SCLC

    67-year-old male Diagnosed in April 2020 with extensive SCLC Location of metastases TLs: liver x2, lymph nodes x2 Non-TLs: liver, lymph nodes x2, spleen, bone, brain Prior systemic treatment Carboplatin + etoposide + toripalimab (anti-PD1) (4 cycles – clinical trial) Cisplatin + etoposide (2 cycles)

  16. Slide 16: Clinical Summary HPN328

    Clinical Summary HPN328 Manageable Safety Profile and Activity at Doses > 1215 µg/week HPN328 is well-tolerated No Grade 3 CRS to date Grade 1-2 CRS in 33% of patients No DLTs MTD not yet identified HPN328 activity signal at doses ≥1215 μg/week: Small Cell Lung Cancer 3 out of 4 patients with target

  17. Slide 17: HPN217 TriTAC Targeting BCMA

    HPN217 TriTAC Targeting BCMA

  18. Slide 18: Multiple Myeloma is a Progressive Disease

    Multiple Myeloma is a progressive disease; depth and duration of response are weak in penta-refractory patients 74% CR /VGPR 58% CR /VGPR 43% CR /VGPR <10% CR /VGPR 1Bird SA, Boyd K. Palliat Care Soc Pract. 2019;13:1-13 3Gandhi, et al., Leukemia. 2019 September ; 33(9): 2266–2275. doi:10.1038/s41375

  19. Slide 19: HPN217-3001 Phase 1/2 Trial Design

    HPN217-3001 Phase 1/2 Trial Design Relapsed/Refractory Multiple Myeloma *International Myeloma Working Group Uniform Response Criteria For Multiple Myeloma and Minimal Residual Disease Assessment in Multiple Myeloma Target Population is R/R MM Disease progressing at time of study entry At least 3 pr

  20. Slide 20: HPN217 Patient Baseline Characteristics

    HPN217 Patient Baseline Characteristics: Heavily Pretreated R/R Multiple Myeloma Population Baseline Characteristics Total N = 37 Age (yr), Median (range) 71 (38 – 78) Duration of Disease (yr), Median (range) 8 (1 – 20) Prior Transplantation, N (%) 28 (76%) Prior Systemic Therapies, Median (range) 7

  21. Slide 21: Reported Adverse Events: HPN217 Has Manageable Safety Profile

    Reported Adverse Events HPN217 Has Manageable Safety Profile Event Grade 1 or Grade 2 ≥ Grade 3 All Grades (N=37) Hematological Adverse Events* Anemia 3 (8%) 14 (38%) 17 (46%) Non-Hematological Adverse Events* Fatigue 11 (30%) 1 (3%) 12 (32%) Aspartate Aminotransferase Increase 2 (5%) 5 (14%) 7 (19%

  22. Slide 22: HPN217 Adverse Events: Focus on CRS

    HPN217 Adverse Events: Focus on CRS No Grade 3 CRS Events Reported to Date Event 5/15/30/90/270 µg/wk (N=7) 810 µg/wk (N=4) 1620 µg/wk (N=6) 2150 µg/wk (N=11) 2860 µg/wk (N=6) 1620→3240 µg/wk (N=3) Total (N=37) CRS (Grade 1 or Grade 2) 0 (0%) 0 (0%) 1 (17%) 6 (55%) 2 (33%) 0 (0%) 9 (24%) CRS Grade 1

  23. Slide 23: HPN217 on Treatment Activity Emerging in Higher Dose Cohorts

    HPN217 on Treatment Activity Emerging in Higher Dose Cohorts Time on Treatment for All Patients Treated Data as of November 10, 2021 IMWG assessments obtained every six weeks 5 15 30 90 270 810 1620 2150 2860 3240

  24. Slide 24: HPN217 IMWG Responses

    HPN217 IMWG Responses Threshold Effect: Responses obtained at higher doses Data as of November 10, 2021 ORR* (PR and better) DCR** (SD and better) Median Time on Treatment (wks) 5 – 810 µg/week 0/11 (0%) 4/11 (36%) 7 (3-25) 1620 µg/week 0/6 (0%) 3/6 (50%) 8 (2-17) 2150 µg/week 5/8 (63%) 7/8 (88%) 12

  25. Slide 25: Clinical Summary HPN217

    Clinical Summary HPN217 Manageable Safety Profile and Active at Doses > 2150 µg/week HPN217 is generally well tolerated Transient low-grade CRS in 24% of patients, no Grade 3 reported to date MTD has not been reached one DLT of Grade 4 AST, resolved HPN217 is active 7 of 8 disease evaluable patients

  26. Slide 26: HPN536 TriTAC Targeting Mesothelin

    HPN536 TriTAC Targeting Mesothelin

  27. Slide 27: HPN536 Phase 1/2a Trial Design and Status

    HPN536 Phase 1/2a Trial Design and Status Mesothelin-Targeting TriTAC Enrolling Late-stage Ovarian, Pancreatic and Mesothelioma Cancer Patients HPN536 escalation study ongoing in multiple indications 83 patients enrolled Target doses up to 3600 ng/kg achieved Now enrolling cohort to evaluate target

  28. Slide 28: HPN424 TriTAC Targeting PSMA

    HPN424 TriTAC Targeting PSMA

  29. Slide 29: HPN424 Trial Design and Status

    HPN424 Trial Design and Status Target Population Disease progression on the prior systemic regimen At least two prior systemic therapies approved for mCRPC Prior chemotherapy allowed, but not required Trial Design Objectives include characterization of safety, PK, pharmacodynamics and identification

  30. Slide 30: HPN424-1001 Phase I Dose Escalation Status Update and Next Steps

    HPN424-1001 Phase I Dose Escalation Status Update and Next Steps 102 patients enrolled across all cohorts Escalation ongoing 450 ng/kg Step Dose Fully Enrolled MTD not identified Safety profile manageable with pre-treatment and step dosing up to 450 ng/kg HPN424 activity seen in patients with reduct

  31. Slide 31: Clinical Summary

    Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase Learnings from earlier programs have enabled rapid dose escalation and effective CRS management Encouraging profile of tolerability and activity seen at higher doses These data va

  32. Slide 32: Harpoon's T Cell Engager Platforms

    Harpoon’s T Cell Engager Platforms

  33. Slide 33: T Cell Engager Platforms Are Optimized to Address Target-Specific Safety Concerns

    T cell Engager Platforms Are Optimized to Address Target-Specific Safety Concerns TriTAC ProTriTAC TriTAC-XR Prodrug Active αALB αTarget αCD3 Finalizing platform validation Maximize systemic exposure while minimizing CRS Heme malignancies and solid tumors with potential expansion to non-oncology Fou

  34. Slide 34: Platforms Designed To Address T Cell Engager Associated Toxicities

    Platforms Designed To Address T Cell Engager Associated Toxicities Prodrug administered systemically Active drug formed through local activation at tumor site Active drug has short half-life Prodrug administered systemically Active drug formed systemically, but in a slow, controlled fashion Active d

  35. Slide 35: Harpoon's First ProTriTAC HPN601 Designed to Target EpCAM

    Harpoon’s First ProTriTAC HPN601 Is Designed to Target EpCAM, Potentially Addressing Large Unmet Medical Need Tumor EpCAM Expression1 (% moderate/high expression by IHC) HPN601 Population2 (estimated annual incidence in USA) Prostate 89 171,000 NSCLC 74 147,000 Breast 46 128,000 Colon 94 99,000 Endo

  36. Slide 36: Committed To Developing Next-Generation T Cell Engagers

    Harpoon Is Committed To Developing Next-Generation T Cell Engagers and Expanding Their Therapeutic Applications Solid tumor Heme Utility TriTAC ✓ ✓ Most robust platform minimizing off-target toxicities ProTriTAC ✓ Spatial control of activity to address on-target tissue damage TriTAC-XR ✓ ✓ Temporal

  37. Slide 37: Financial Snapshot

    Notes Cash, Cash Equivalents and Marketable Securities $154.2M Expected to fund operations into 1H 2023 No debt As of September 30, 2021 Shares Outstanding 32.7M As of October 31, 2021 Market Capitalization $247M As of December 31, 2021 Non-affiliated Institutional Ownership 51.4% As of January 6, 2

  38. Slide 38: 2022 Harpoon Milestones

    Program Milestone Anticipated Timing HPN217 Select the recommended Phase 2 dose (RP2D) and initiate expansion cohort(s) 1H 2022 Platform technology and selected clinical data R&D Day 1H 2022 HPN424 Complete dose escalation 2H 2022 Platform technologies Move new clinical candidate into IND-enabling s

  39. Slide 39: Summary & Conclusions

    Summary & Conclusions HARP: a clinical-Stage immuno-oncology company developing three novel classes of T cell engagers TriTAC ProTriTAC TriTAC XR Four TriTACs in clinical development in US, UK and EU All programs in dose-escalation across multiple indications All levels of target expression eligible

  40. Slide 40: Spearheading Immunotherapies

    Spearheading Immunotherapies

Harpoon Therapeutics — Investor Presentation (January 2022) on 6ix